FSS logo.png
Frontier Science Scotland Strengthens Board of Trustees with New Appointment
June 17, 2024 04:00 ET | Frontier Science Scotland
KINCRAIG, Scotland, June 17, 2024 (GLOBE NEWSWIRE) -- Frontier Science Scotland (FSS), a leading contract clinical research organisation, advancing drug development by delivering excellence in...
CenExel Highlights H
CenExel Highlights High Level of Psychometric Rater Stress and Burnout
May 29, 2024 13:00 ET | CenExel Clinical Research
Salt Lake City, Utah, May 29, 2024 (GLOBE NEWSWIRE) -- Poster presented today at American Society of Clinical Pharmacology (ASCP) Annual Meeting in Miami Beach, Florida, shows: High levels of...
inmunebio.jpg
INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα
October 30, 2023 09:07 ET | INmune Bio, Inc.
SIRP-CD47 is an innate immune checkpoint known as the “don’t eat me” signal. INB03 downregulates expression of SIRPα on macrophages promote increased cancer cell death by antibody dependent cellular...
purple-logo2020.png
Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action
October 06, 2023 07:50 ET | Purple Biotech Ltd.
REHOVOT, Israel, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that...
purple-logo2020.png
Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
October 03, 2023 07:50 ET | Purple Biotech Ltd.
Anti-tumor activity noted in the highest dose cohort of NT219 in combination with cetuximab;  2 out of 4 SCCHN patients at the highest dose cohort demonstrated a confirmed partial responseNT219...
scilogo.jpg
SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder
September 29, 2023 07:45 ET | SciSparc Ltd
TEL AVIV, Israel, Sept. 29, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
LOGO roboto color with gray.png
Folia Health launches user-led research program, the Canopy Series
May 23, 2023 10:09 ET | Folia Health
BOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- Today, Folia Health announced a first-of-its-kind observational research initiative driven by the priorities of patient and caregiver users. This program,...
sensus_logo.jpg
Sensus Healthcare's SRT Treatment Shows Promise in Treating Cutaneous Mast Cell Tumors Among Pet Patients
May 17, 2023 08:00 ET | Sensus Healthcare, Inc.
BOCA RATON, Fla, May 17, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare Inc. (Nasdaq:SRTS), the leading manufacturer of advanced medical devices for non-surgical skin cancer and keloid scar treatment,...
scilogo.jpg
SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer's Disease and Agitation
May 02, 2023 07:25 ET | SciSparc Ltd
The Company previously announced positive interim results from the trial meeting its primary endpoints TEL AVIV, Israel, May 02, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or...
Coya Therapeutics White Background.jpg
Coya Therapeutics, Inc. Announces Peer-Reviewed Publication of Phase 2a Clinical Trial Data for COYA 101 in Amyotrophic Lateral Sclerosis (ALS)
September 01, 2022 09:27 ET | Coya Therapeutics, Inc.
Phase 2a publication entitled “Combined Regulatory T-Lymphocyte and IL-2 Treatment is Safe, Tolerable, and Biologically Active for One Year in Persons with Amyotrophic Lateral Sclerosis” has been...